Table 1.

Overview of the main active and recently concluded clinical trials of drugs targeting tumor metabolism in melanoma (source: clinicaltrials.gov; accessed on 17 April 2021).

Trial Name, NCT Number	Phase	Condition(s)	Drug(s)	Metabolic Target(s)	Objective(s)	Status
NCT03207867	II	Advanced solid tumors DLBCL	NIR178 Spartalizumab (PDR001)	ADO	ORR, DCR, DOR PFS AEs PK Changes in the immune infiltrate Presence of PDR001 Ab	Active, recruiting
NCT03047928	I/II	Advanced melanoma	PD-L1/IDO peptide vaccine Nivolumab	PD-L1-IDO	AEs Treatment-related immune responses ORR OS, PFS	Active, recruiting
NCT04007588	II	Resectable stage III/IV melanoma	Linrodostat (BMS986205) Nivolumab Ipilimumab	IDO	mPCR RFS, OS Changes in the immune infiltrate AEs	Withdrawn (slow accrual)
NCT02073123	I/II	Advanced melanoma	Indoximod Nivolumab Pembrolizumab Ipilimumab	IDO	AEs ORR, DCR Mechanisms of activity/resistance to IDO/CTLA-4 inhibitor therapy OS, PFS	Completed
ECHO-208, NCT03347123	I/II	Advanced solid tumors	Epacadostat Nivolumab Ipilimumab Lirilumab	IDO KIR2DL1/2L3	AEs ORR, DOR PFS	Completed
NCT04148937	I	Advanced solid tumors	LY3475070 Pembrolizumab	CD73	DLT PK ORR, DOR PFS	Active, recruiting
PANAMA, NCT02702492	I	Advanced solid tumors NHL	KPT-9274 Niacin ER Nivolumab	PAK4 NAMPT	MTD	Active, recruiting

Abbreviations: Ab, antibodies; ADO, adenosine; AEs, adverse events; CTLA-d1, cytotoxic T lymphocyte Antigen 4; DCR, disease control rate; DLBCL, diffuse large B cell lymphoma; DLT, dose-limiting toxicity; DOR, duration of response; ER, extended release; IDO, indoleamine 2,3-dioxygenase; KIR2DL1/2L3, killer-cell immunoglobulin like receptor; mPCR, major pathologic response; MTD, maximum tolerated dose; NAMPT, nicotinamide phopshorybosiltransferase; NHL, non-Hodgkin lymphoma; ORR, objective response rate; OS, overall survival; PD-L1, programmed cell death ligand 1; PK, pharmacokinetics; PFS, progression-free survival; RFS, relapse-free survival.